Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer.

At the planned primary analysis of the all-comers cohort, the median rPFS was not yet reached in the experimental arm for the intention-to-treat cohort, with a clear trend favouring the combination (NR vs 21.9 months, HR 0.63 [95% CI 0.51–0.78], p = <0.0001), suggesting that the combination confers a clinically meaningful benefit regardless of HRR status [ 59 ].

also in 19,460 other papers